Yusuke Horio

• Completed a cross-border asset divestiture transaction with a Chinese conglomerate company in FY2021 • Strategically terminated the GI business with an European partner to improve corporate profit and focus internal resource into the organic business in FY2023 • Facilitated the mature business divestiture to a Singapore based asset management firm in FY2024, which contributed more than 100 Mn USD profit

• Formulated the comprehensive partnership for generic business with one of the largest J-generic companies in FY2019 • Entered into the license-in agreement for the primary care medicine about development and commercialization in FY2019 • Co-development agreement of novel pain management agent for knee OA in FY 2020

• Organized "Marketing Excellence Workshop" collaborated with AstraZeneca Hong Kong • Participated "Healthtech O2O SUMMIT" as a staff for networking with healthtech startups • Visited Pfizer Hong Kong to explore the healthcare business opportunity in Hong Kong and emerging market in Asia

Analyzed and communicated with startups in Blockchain, Fintech, and Healthtech from all over the world to organize the O2O international conference in Hong Kong, more than 1000 professionals participate

How to Leverage Big Bay Area to Strengthen Hong Kong as Medical Center of Excellence - Given the policy of Belt and Road, the Big Bay advocation creates various opportunities for Hong Kong. In this Business Practicum sponsored by AstraZeneca, we have identified the opportunities for Hong Kong as a medical hub of the Big Bay Area. - Conducted a market research from 14 organizations for Greater Bay Area in Mainland China and Hong Kong aiming for creating a new market for the latest cancer therapy, and suggested market expansion strategy for immune cancer drugs

2 in-licensing deals • Completed distribution agreement for narcotic analgesic in Japan territory in order to enhance company portfolio strategy (2017) • Collaborated with academia derived biotech company for development of clinical compounds leading 20-person project team including R&D, marketing, and legal staff to implement due diligence, appraise potential risks and clarify the future benefits (2015)

• 1 of 5 employees chosen from 1100 for a 3-year Executive Trainee Development Program (2014); selected based on sales record and potential • Won the Excellent Brand Manager Award for expanding network for sales of Cymbalta® in October 2012 • Formulated the business strategy liaising with product marketing team, medical representatives, and medical doctors; successfully expanded anti-depressant sales by 10% (the highest in region) and achieved 6 consecutive quarterly sales goals • Mentored 3 junior medical representatives to increase market share of newly launched medicine; held
weekly meetings for training and problem solving

• Achieved the highest sales and market share, approximately 40%, among over 1000 medical representatives in company for new product launched in 2010 • Won the Internal Best Wholesaler Promoter Award in April 2010 • Won the Best Partnership Award from a French alliance partner in December 2009 • Conducted 10 medical training seminars on infectious prevention in hospitals, palliative care for cancer patients, and proper use of psychotropic agents intended for physicians, pharmacists, and nurses in hospitals; attracted 20-100 participants for each

#Ranked 36th in the Financial Times Global MBA Ranking 2017 and 14th in the Financial Times Top MBAs for finance 2017 • HKUST Global MBA Challenge 2018 finalist - 2nd runner-up for flash case round -